CN109195985B - Pd-1和4-1bb的融合蛋白 - Google Patents

Pd-1和4-1bb的融合蛋白 Download PDF

Info

Publication number
CN109195985B
CN109195985B CN201780031958.9A CN201780031958A CN109195985B CN 109195985 B CN109195985 B CN 109195985B CN 201780031958 A CN201780031958 A CN 201780031958A CN 109195985 B CN109195985 B CN 109195985B
Authority
CN
China
Prior art keywords
leu
ser
cells
fusion protein
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780031958.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN109195985A (zh
Inventor
E·诺瑟纳
R·施伦克
S·韦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Publication of CN109195985A publication Critical patent/CN109195985A/zh
Application granted granted Critical
Publication of CN109195985B publication Critical patent/CN109195985B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201780031958.9A 2016-03-23 2017-03-23 Pd-1和4-1bb的融合蛋白 Active CN109195985B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU93006 2016-03-23
LULU93006 2016-03-23
PCT/EP2017/056931 WO2017162797A1 (en) 2016-03-23 2017-03-23 Fusion proteins of pd-1 and 4-1bb

Publications (2)

Publication Number Publication Date
CN109195985A CN109195985A (zh) 2019-01-11
CN109195985B true CN109195985B (zh) 2022-07-26

Family

ID=55702054

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780031958.9A Active CN109195985B (zh) 2016-03-23 2017-03-23 Pd-1和4-1bb的融合蛋白

Country Status (8)

Country Link
US (3) US11365237B2 (enExample)
EP (2) EP4286522A3 (enExample)
JP (2) JP7250519B2 (enExample)
CN (1) CN109195985B (enExample)
AU (1) AU2017236069B2 (enExample)
CA (1) CA3017036A1 (enExample)
ES (1) ES2962588T3 (enExample)
WO (1) WO2017162797A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180029201A (ko) 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
EP4286522A3 (en) * 2016-03-23 2024-02-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
CA3038150A1 (en) * 2016-12-22 2018-06-28 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
WO2018181390A1 (ja) 2017-03-31 2018-10-04 東亞合成株式会社 Ｐｄ－１シグナル配列を有する抗腫瘍ペプチドおよびその利用
SG11202013170RA (en) * 2018-07-11 2021-01-28 Kahr Medical Ltd Pd1-4-1bbl variant fusion protein and methods of use thereof
KR102351041B1 (ko) * 2018-12-19 2022-01-13 한국화학연구원 인간 lrrc24 단백질 유래 세포막 투과 도메인
WO2020146423A1 (en) * 2019-01-07 2020-07-16 Thomas Jefferson University Multi-functional fusion proteins and uses thereof
EP3999079A4 (en) * 2019-07-19 2024-04-03 Memorial Sloan Kettering Cancer Center Fusion polypeptide for immunotherapy
CN115956086A (zh) * 2020-05-06 2023-04-11 萨摩亚商柏沛生医股份有限公司 用于针对癌症及传染病的免疫疗法的融合蛋白
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
WO2023025779A1 (en) * 2021-08-25 2023-03-02 Medigene Immunotherapies Gmbh Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors
JP2025527657A (ja) * 2022-08-23 2025-08-22 メディジーン イミュノテラピーズ ゲーエムベーハー Ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体とキメラ共刺激受容体との組み合わせ物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141520A1 (es) * 2011-07-29 2014-11-17 Univ Pennsylvania Receptores coestimuladores de cambio
KR101471647B1 (ko) * 2011-10-26 2014-12-11 국립암센터 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CN105518018B (zh) * 2013-03-15 2020-04-03 细胞基因公司 修饰的t淋巴细胞
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
BR112015027567B1 (pt) 2013-05-03 2024-02-20 Ohio State Innovation Foundation Polipeptídeo, sequência de ácido nucleico isolada, vetor, método de obtenção de célula, uso de uma célula
WO2015142675A2 (en) * 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
SG10201900455YA (en) * 2014-07-24 2019-02-27 Bluebird Bio Inc Bcma chimeric antigen receptors
US20170209492A1 (en) * 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
CA2973529A1 (en) * 2015-01-26 2016-08-04 Cellectis Cll1-specific multi-chain chimeric antigen receptor
AU2015380397B2 (en) * 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
CA2976684C (en) * 2015-03-02 2024-03-05 Innovative Cellular Therapeutics CO., LTD. Reducing immune tolerance induced by pd-l1
CN107531805A (zh) * 2015-03-05 2018-01-02 弗雷德哈钦森癌症研究中心 免疫调节融合蛋白及其用途
KR20180029201A (ko) * 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
CN104829733B (zh) 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
PT3310805T (pt) * 2015-06-19 2021-05-19 Kobold Sebastian Proteínas de fusão pd-1-cd28 e a sua utilização em medicina
HK1255637A1 (zh) * 2015-06-29 2019-08-23 The Johns Hopkins University 免疫检查点嵌合受体疗法
EP3344284A1 (en) * 2015-09-04 2018-07-11 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
AU2017230011A1 (en) * 2016-03-11 2018-09-27 2Seventy Bio, Inc. Genome edited immune effector cells
EP4286522A3 (en) * 2016-03-23 2024-02-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
WO2019169290A1 (en) * 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
EP3774906A1 (en) * 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof

Also Published As

Publication number Publication date
AU2017236069B2 (en) 2021-04-08
CA3017036A1 (en) 2017-09-28
US11365237B2 (en) 2022-06-21
ES2962588T3 (es) 2024-03-20
US20220380435A1 (en) 2022-12-01
NZ745944A (en) 2025-05-30
JP7250519B2 (ja) 2023-04-03
JP2023078362A (ja) 2023-06-06
AU2017236069A1 (en) 2018-09-20
US20240247046A1 (en) 2024-07-25
EP4286522A3 (en) 2024-02-28
CN109195985A (zh) 2019-01-11
JP7746323B2 (ja) 2025-09-30
US20190106478A1 (en) 2019-04-11
EP3433269C0 (en) 2023-09-27
EP3433269A1 (en) 2019-01-30
EP4286522A2 (en) 2023-12-06
WO2017162797A1 (en) 2017-09-28
JP2019512251A (ja) 2019-05-16
EP3433269B1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
CN109195985B (zh) Pd-1和4-1bb的融合蛋白
JP7460675B2 (ja) Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
US12162922B2 (en) Enhanced antigen presenting ability of RNA car T cells by co-introduction of costimulatory molecules
KR102614675B1 (ko) 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
JP2022058681A (ja) 受容体
CN111836827B (zh) 包含nkg2d结构域的多特异性嵌合受体和其使用方法
KR20170120701A (ko) 면역조절 융합 단백질 및 그 용도
CN111566124A (zh) 制备表达嵌合抗原受体的细胞的方法
KR20180028528A (ko) 치료제
KR20180021137A (ko) 키메라 항원 수용체 (car), 조성물 및 이의 사용 방법
KR20180042361A (ko) 통합된 통제가능한 기능들을 가진 키메라 항원 수용체들
JP2021527425A (ja) キメラ増殖因子受容体
JP2024509917A (ja) 腫瘍溶解性ウイルスによる直交性ｉｌ－２の送達を用いた、固形腫瘍におけるｔ細胞の選択的刺激方法
Olguín-Contreras et al. Double strike approach for tumor attack: engineering T cells using a CD40L: CD28 chimeric co-stimulatory switch protein for enhanced tumor targeting in adoptive cell therapy
CN112996819B (zh) 细胞分选系统及使用方法
US12410231B2 (en) Natural killer cell products and methods
CN114450307B (zh) 基因工程细胞及其用途
RU2824672C2 (ru) Конститутивно активные химерные цитокиновые рецепторы
HK40066141A (zh) 基因工程细胞及其用途
HK40066141B (zh) 基因工程细胞及其用途
CN117157407A (zh) 编码ap-1转录因子的密码子优化的核苷酸序列
HK40058918B (zh) A2/ny-eso-1特异性t细胞受体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant